144 related articles for article (PubMed ID: 10864206)
1. Expression of transcription factor AP-2alpha predicts survival in epithelial ovarian cancer.
Anttila MA; Kellokoski JK; Moisio KI; Mitchell PJ; Saarikoski S; Syrjänen K; Kosma VM
Br J Cancer; 2000 Jun; 82(12):1974-83. PubMed ID: 10864206
[TBL] [Abstract][Full Text] [Related]
2. Loss of the AP-2alpha transcription factor is associated with the grade of human gliomas.
Heimberger AB; McGary EC; Suki D; Ruiz M; Wang H; Fuller GN; Bar-Eli M
Clin Cancer Res; 2005 Jan; 11(1):267-72. PubMed ID: 15671555
[TBL] [Abstract][Full Text] [Related]
3. Activator protein 2alpha transcription factor expression is associated with luminal differentiation and is lost in prostate cancer.
Ruiz M; Troncoso P; Bruns C; Bar-Eli M
Clin Cancer Res; 2001 Dec; 7(12):4086-95. PubMed ID: 11751506
[TBL] [Abstract][Full Text] [Related]
4. Reduced nuclear expression of transcription factor AP-2 associates with aggressive breast cancer.
Pellikainen J; Kataja V; Ropponen K; Kellokoski J; Pietiläinen T; Böhm J; Eskelinen M; Kosma VM
Clin Cancer Res; 2002 Nov; 8(11):3487-95. PubMed ID: 12429639
[TBL] [Abstract][Full Text] [Related]
5. [Expression of p21(WAF1) and its relationship with p53 and PCNA protein in epithelial ovarian cancer].
Yan XJ; Liang LZ; Li DC; Li JL; Zhang CQ; Yuan SH
Ai Zheng; 2004 Jan; 23(1):74-80. PubMed ID: 14720380
[TBL] [Abstract][Full Text] [Related]
6. Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival.
Rosen DG; Wang L; Jain AN; Lu KH; Luo RZ; Yu Y; Liu J; Bast RC
Clin Cancer Res; 2004 Oct; 10(19):6559-66. PubMed ID: 15475444
[TBL] [Abstract][Full Text] [Related]
7. Failure in post-transcriptional processing is a possible inactivation mechanism of AP-2alpha in cutaneous melanoma.
Karjalainen JM; Kellokoski JK; Mannermaa AJ; Kujala HE; Moisio KI; Mitchell PJ; Eskelinen MJ; Alhava EM; Kosma VM
Br J Cancer; 2000 Jun; 82(12):2015-21. PubMed ID: 10864211
[TBL] [Abstract][Full Text] [Related]
8. Expression of HER2 and its association with AP-2 in breast cancer.
Pellikainen J; Naukkarinen A; Ropponen K; Rummukainen J; Kataja V; Kellokoski J; Eskelinen M; Kosma VM
Eur J Cancer; 2004 Jul; 40(10):1485-95. PubMed ID: 15196531
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical analysis reveals a tumour suppressor-like role for the transcription factor AP-2 in invasive breast cancer.
Gee JM; Robertson JF; Ellis IO; Nicholson RI; Hurst HC
J Pathol; 1999 Dec; 189(4):514-20. PubMed ID: 10629551
[TBL] [Abstract][Full Text] [Related]
10. Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma.
Davidson B; Reich R; Lazarovici P; Nesland JM; Skrede M; Risberg B; Tropé CG; Flørenes VA
Clin Cancer Res; 2003 Jun; 9(6):2248-59. PubMed ID: 12796393
[TBL] [Abstract][Full Text] [Related]
11. Evidence for a dose-response effect between p53 (but not p21WAF1/Cip1) protein concentrations, survival, and responsiveness in patients with epithelial ovarian cancer treated with platinum-based chemotherapy.
Levesque MA; Katsaros D; Massobrio M; Genta F; Yu H; Richiardi G; Fracchioli S; Durando A; Arisio R; Diamandis EP
Clin Cancer Res; 2000 Aug; 6(8):3260-70. PubMed ID: 10955812
[TBL] [Abstract][Full Text] [Related]
12. Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma.
Davidson B; Reich R; Goldberg I; Gotlieb WH; Kopolovic J; Berner A; Ben-Baruch G; Bryne M; Nesland JM
Clin Cancer Res; 2001 Mar; 7(3):551-7. PubMed ID: 11297247
[TBL] [Abstract][Full Text] [Related]
13. Expression of transcription factor AP-2 in colorectal adenomas and adenocarcinomas; comparison of immunohistochemistry and in situ hybridisation.
Ropponen KM; Kellokoski JK; Pirinen RT; Moisio KI; Eskelinen MJ; Alhava EM; Kosma VM
J Clin Pathol; 2001 Jul; 54(7):533-8. PubMed ID: 11429425
[TBL] [Abstract][Full Text] [Related]
14. Transcription factor AP-2gamma is a developmentally regulated marker of testicular carcinoma in situ and germ cell tumors.
Hoei-Hansen CE; Nielsen JE; Almstrup K; Sonne SB; Graem N; Skakkebaek NE; Leffers H; Rajpert-De Meyts E
Clin Cancer Res; 2004 Dec; 10(24):8521-30. PubMed ID: 15623634
[TBL] [Abstract][Full Text] [Related]
15. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis.
Pellikainen JM; Ropponen KM; Kataja VV; Kellokoski JK; Eskelinen MJ; Kosma VM
Clin Cancer Res; 2004 Nov; 10(22):7621-8. PubMed ID: 15569994
[TBL] [Abstract][Full Text] [Related]
16. Transcriptional factor AP-2gamma increases human cystatin A gene transcription of keratinocytes.
Takahashi H; Oyama N; Itoh Y; Ishida-Yamamoto A; Kaneko F; Iizuka H
Biochem Biophys Res Commun; 2000 Nov; 278(3):719-23. PubMed ID: 11095974
[TBL] [Abstract][Full Text] [Related]
17. Level of Id-1 protein expression correlates with poor differentiation, enhanced malignant potential, and more aggressive clinical behavior of epithelial ovarian tumors.
Schindl M; Schoppmann SF; Ströbel T; Heinzl H; Leisser C; Horvat R; Birner P
Clin Cancer Res; 2003 Feb; 9(2):779-85. PubMed ID: 12576450
[TBL] [Abstract][Full Text] [Related]
18. Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer.
Wang L; Hoque A; Luo RZ; Yuan J; Lu Z; Nishimoto A; Liu J; Sahin AA; Lippman SM; Bast RC; Yu Y
Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3660-6. PubMed ID: 14506155
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of activator protein-2 isoforms in renal cell carcinoma.
Oya M; Mikami S; Mizuno R; Miyajima A; Horiguchi Y; Nakashima J; Marumo K; Mukai M; Murai M
Urology; 2004 Jul; 64(1):162-7. PubMed ID: 15245963
[TBL] [Abstract][Full Text] [Related]
20. PEA3 is the second Ets family transcription factor involved in tumor progression in ovarian carcinoma.
Davidson B; Goldberg I; Gotlieb WH; Kopolovic J; Ben-Baruch G; Reich R
Clin Cancer Res; 2003 Apr; 9(4):1412-9. PubMed ID: 12684413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
